EDAN Announces 2020 Annual Results and 2025 Outlook: Revenues Increased 104.1% Just and before 2025
PR88524
SHENZHEN, China, March 16, 2021 /PRNewswire=KYODO JBN/ --
EDAN Instruments, Inc.(http://www.edan.com/) ("EDAN" or the "Company) (SHE:
300206) on Monday announced its results for the preceding fiscal year (FY 2020)
with revenue of CNY 2.3 billion. The company also revealed its strategic 5+1
plan and its anticipation for 2025.
EDAN's 2020 Financial Highlights (all results compared to FY 2019)
-Revenues increased 104.1% to CNY 2.3 billion, in which CNY 1.4 billion are
from Patient Monitoring products with a 270.65% increment compared to FY 2019
-Net profit attributed to shareholders reached CNY 653 million vs. CNY 131.3
million
-Operating income increased 447% to CNY 745 million
-Net cash from operating activities increased 498% to CNY 689 million
-CNY 250 million in dividends paid to shareholders in 2020
For FY 2020, EDAN reported dispatching hundreds of thousands of medical
equipment to over 140 countries(https://www.youtube.com/watch?v=RzUHmzKilaU).
Apart from the 270.7% increment in patient monitoring, the report reflects all
five product lines show increment in FY 2020, including a 41.5% increment in
In-Vitro Diagnostics & Point-of-Care Testing to CNY 210 million. Throughout the
year, EDAN established its brand and recognition in the market by delivering
high-quality medical equipment to publicly funded healthcare systems,
purchasing organizations, and hospitals like the Nation Health
Service(http://www.edan.com/news/company101/79.html) (NHS, UK) and
AP-HP(http://www.edan.com/news/company101/74.html).
Under the universal operational challenges, EDAN maintained a steady increment
in its R&D investments, from CNY 194.6 million to CNY 218.0 million. To ramp up
the productivity, the company added production lines as well as introduced the
automating supply chain.
Hao Zhang, Chairman and Chief Executive Officer of EDAN, commented in his
letter to EDAN's shareholders, "The achievements we did in 2020 were achieved
by all of our employees, business partners, and stakeholders, even in such
global uncertainties. What we did showed resilience, accumulates, and a sense
of responsibility, especially when making decisive actions. EDAN were managed
to serve our clients across the world with timely delivery while prioritizing
our people and clients during the pandemic."
The 5+1 plan, the outlook for 2020 to 2025, was further discussed in the
letter. "To achieve revenue of CNY 5 billion in 2025, periodical targets were
set by each unit, product-wise, operation-wise and strategic-wise. Local
subsidiaries are also planned to excavate niche markets and provide better
services to our clients."
"What's past is prologue. At the start of the 5+1 Plan, EDAN and I will keep
our mission in mind, and creating value for shareholders and society as
always," Zhang concludes.
About EDAN Instruments, Inc.
Edan is a healthcare company dedicated to improving the human condition around
the world by delivering value-driven, innovative, and high-quality medical
products and services. For over 20 years, Edan has been pioneering a
comprehensive line of medical solutions that address a broad range of
healthcare practices including Diagnostic
ECG(http://www.edan.com/product/ecg/), OB/GYN(http://www.edan.com/product/ob/),
Ultrasound Imaging(http://www.edan.com/product/ultrasound/), In-Vitro
Diagnostics(http://www.edan.com/product/ivd/), Patient
Monitoring(http://www.edan.com/product/patient/), Point-of-Care
Testing(http://www.edan.com/product/poct/), and
Veterinary(http://www.edan.com/product/veterinary/). Healthcare professionals
around the world depend on Edan's breakthrough medical technologies and
outstanding customer support.
Source: EDAN Instruments, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。